Arcus Biosciences, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $247.0M | $258.0M | $117.0M | $112.0M | $383.0M | $78.0M | $15.0M | $8.4M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $523.0M | $448.0M | $340.0M | $288.0M | $257.0M | $159.0M | $78.5M | $49.6M |
| SG&A Expense | $110.0M | $120.0M | $117.0M | $104.0M | $72.0M | $43.0M | $25.2M | $13.6M |
| Operating Income | $-386.0M | $-330.0M | $-340.0M | $-280.0M | $54.0M | $-124.0M | $-88.7M | $-54.9M |
| Operating Margin | -156.3% | -127.9% | -290.6% | -250.0% | 14.1% | -159.0% | -591.4% | -656.8% |
| Interest Expense | $9.0M | $2.0M | — | — | — | — | — | — |
| Pretax Income | $-353.0M | $-282.0M | $-301.0M | $-266.0M | $55.0M | $-123.0M | $-84.7M | — |
| Income Tax Expense | $0 | $1.0M | $6.0M | $1.0M | $2.0M | — | — | — |
| Net Income | $-353.0M | $-283.0M | $-307.0M | $-267.0M | $53.0M | $-123.0M | $-84.7M | $-49.6M |
| Net Margin | -142.9% | -109.7% | -262.4% | -238.4% | 13.8% | -157.7% | -564.7% | -593.7% |
| EPS (Basic) | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.76 | $-2.24 | $-1.93 | $-1.43 |
| EPS (Diluted) | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.71 | $-2.24 | $-1.93 | $-1.43 |
| Shares Outstanding (Basic) | 107.4M | 90.1M | 74.0M | 72.0M | 69.3M | 54.8M | 43.8M | 36.4M |
| Shares Outstanding (Diluted) | 107.4M | 90.1M | 74.0M | 72.0M | 74.0M | 54.8M | 43.8M | 36.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |